AUG 28, 2015 09:39 PM PDT

Promising Drug Target in Pancreatic Cancer Cells

Pancreatic cancer, the fourth deadliest cancer in the U.S., is very hard to detect in its early stages. Rarely diagnosed early and usually spreading rapidly, the disease has a poor prognosis. University of Houston researchers are seeking to develop drugs to enable physicians to prolong patient survival and, possibly, even eradicate pancreatic cancer, according to an article in Drug Discovery & Development
Professor Chin-Yo Lin works with Ph.D. student Sridevi Addanki in his lab at the Center for Nuclear Receptors and Cell Signaling in the College of Natural Sciences and Mathematics at the University of Houston. 
According to cancer biologist Chin-Yo Lin, an assistant professor with the UH Center for Nuclear Receptors and Cell Signaling (CNRCS), "Our research on the role of liver X receptors, or LXRs, in pancreatic cancer cells points to a promising target and strategy in the treatment of pancreatic cancer. We examined the levels of LXRs in patient tumor samples and studied the effects of candidate drug compounds targeting LXRs on cultured pancreatic cancer cells."
 
Lin explained that liver X receptors are key regulators of cholesterol, glucose metabolism and inflammatory response modulation. In collaboration with CNRCS director Dr. Jan-Åke Gustafsson, a pioneer in the discovery of LXRs and the Robert A. Welch Professor in Biology and Biochemistry in the UH College of Natural Sciences and Mathematics, Lin has helped to amass evidence to implicate the involvement of LXRs in numerous malignancies.
 
The researchers expect their ongoing studies to help determine whether LXRs are expressed in all tumors or a specific subset of tumors that could be sensitive to drugs targeting LXRs. Another objective is to determine the effects of the drugs on pancreatic tumors in mouse models that are similar to those found in humans. Eventually, they anticipate using the knowledge from these studies to develop better drugs to target LXRs in pancreatic cancer and other malignancies.
 
The team has done some preliminary studies of LXR expression in patient tumor samples and is preparing to investigate more samples. Recent studies demonstrated that chemical compounds targeting LXRs can retard the growth of tumors in murine models transplanted with human tumor cells.
 
As Lin said, "Our findings point to a class of receptors that can be precisely targeted by drug compounds and are expected to stimulate both basic and translational research on their functions and application as a drug target. Long-term goals are to develop additional drug compounds and clinical testing in human subjects, which will require several more years of research."
 
He concluded, "Our next steps are to collect more information from patient samples and data from pre-clinical studies. Based on the results, we will then move forward with clinical studies using existing compounds or partner with biotech or pharmaceutical companies to develop better drug candidates."
 
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 31, 2018
Cancer
JUL 31, 2018
Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?
DNA replication is a carefully regulated process in each cell of the body. Researchers are looking at the mechanism of DNA replication and associated proteins as a therapy target in cancer...
AUG 14, 2018
Cancer
AUG 14, 2018
New Drug for Refractory Cutaneous T-cell Lymphoma
Mogamulizumab was approved by the FDA this month after a very successful Phase III clinical trial demonstrating its effectiveness in treating patients with challenging CTCL....
AUG 28, 2018
Drug Discovery
AUG 28, 2018
Combination Therapy for Advanced Melonoma
According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with a...
SEP 04, 2018
Cancer
SEP 04, 2018
Metal beads that could help reduce chemotherapy side effects in brain tumor
Brain tumors are one of the most challenging types of cancers to treat. Only 1 in 7 patients will survive the disease, and those survivors will usually suffer from lots of side effects becaus...
OCT 21, 2018
Technology
OCT 21, 2018
New Technology Detects Early-Stage Lung Cancer
According to recent research published in the Journal of Molecular Diagnostics, outcomes of patients with non-small-cell lung carcinoma (NSCLC) may be impr...
OCT 31, 2018
Drug Discovery
OCT 31, 2018
New Drug Target For a Rare Lymphoma
The promise of immunotherapy in oncology is stronger than ever. Now, an international team of scientists and physicians from the Research Institute of the ...
Loading Comments...